A failure to warn lawsuit is a type of products liability claim that holds manufacturers and sellers responsible when they fail to provide adequate warnings about dangers or risks associated with their products. Specifically, under strict liability principles established in product liability law, a seller can be held liable for injuries caused by a product if a feasible warning was absent and that absence contributed to the plaintiff’s harm. For example, the ongoing Roundup litigation involves hundreds of thousands of claimants alleging that Bayer failed to adequately warn consumers that the herbicide’s active ingredient, glyphosate, poses a cancer risk—a claim that has resulted in tens of thousands of pending lawsuits and billions in settlement proposals.
Unlike defective design or manufacturing defect claims, failure to warn cases focus specifically on whether the manufacturer knew or should have known about a danger and whether it had a duty to communicate that danger to end-users. The legal threshold is not perfection or warning about every conceivable risk, but rather ensuring that any feasible and necessary warnings are provided and that they are adequate in content, placement, and visibility. These cases have become increasingly prominent in mass tort litigation, affecting everything from pesticides and pharmaceuticals to consumer products, and they continue to reshape how companies approach product safety and labeling.
Table of Contents
- WHAT LEGAL STANDARDS DEFINE A FAILURE TO WARN CLAIM?
- THE CRITICAL ELEMENTS AND CAUSATION CHALLENGES
- ROUNDUP AND GLYPHOSATE—THE DEFINING LITIGATION OF THE ERA
- HOW THE SUPREME COURT’S PREEMPTION RULING COULD RESHAPE FAILURE TO WARN LAW
- OTHER MAJOR FAILURE TO WARN CASES CURRENTLY ACTIVE
- BUILDING A FAILURE TO WARN CASE: WHAT EVIDENCE MATTERS
- THE EVOLVING LANDSCAPE AND FUTURE OF FAILURE TO WARN LITIGATION
- Conclusion
WHAT LEGAL STANDARDS DEFINE A FAILURE TO WARN CLAIM?
A failure to warn claim has three essential elements that a plaintiff must establish. First, the defendant had a duty to warn about the product hazard. Second, the warning or instructions were inadequate—either absent, insufficient in detail, or improperly communicated. Third, the inadequate warning or absence of a warning was a substantial factor in causing the plaintiff’s injury. California Civil Jury Instruction (CACI) 2026 codifies this strict liability standard, which places the burden on manufacturers to warn of known or knowable risks, even if they weren’t explicitly proved before the product was marketed.
The critical distinction in failure to warn cases is that the plaintiff does not have to prove the manufacturer was negligent or reckless. Rather, under strict liability doctrine, once a product is determined to be defective because of inadequate warnings, liability follows automatically. This is different from a negligence claim, which would require proving the manufacturer breached a reasonable standard of care. Consequently, even a manufacturer that exercised reasonable care can still face liability if a feasible warning could have prevented injury. A warning is considered “feasible” if it was economically and technologically practical for the manufacturer to include it before the product reached the consumer.
THE CRITICAL ELEMENTS AND CAUSATION CHALLENGES
Establishing that a warning was “feasible” involves examining whether the manufacturer had the practical ability to discover the hazard and communicate it. The challenge lies in the causation prong—a plaintiff must prove not only that a warning should have been given, but that if the warning had been provided and read, it would have altered the user’s behavior and prevented injury. This causation element is where many failure to warn cases falter, particularly when dealing with warnings about risks that consumers might dismiss or ignore.
In practice, this means that even if a manufacturer knew about a hazard, the case could still fail if the plaintiff cannot demonstrate that a reasonable warning would have changed their conduct. Courts often examine the nature of the hazard, the foreseeability of the product being used in the manner that caused injury, and the efficacy of alternative warnings that might have been provided. Additionally, some jurisdictions recognize a “learned intermediary” doctrine, which may relieve manufacturers of their duty to warn end-consumers directly if they have adequately warned doctors, pharmacists, or other professionals who stand between the product and the user. This limitation is particularly significant in pharmaceutical cases, where the expectation is that physicians will communicate risks to patients.
ROUNDUP AND GLYPHOSATE—THE DEFINING LITIGATION OF THE ERA
The Roundup litigation represents the largest and most visible failure to warn mass tort in recent legal history. As of January 2026, approximately 4,511 pending cases remain in the Northern District of California MDL (multidistrict litigation) focused on Roundup’s alleged cancer risks. Beyond that consolidated docket, roughly 65,000 active lawsuits continue nationwide, even after Bayer’s earlier settlements resolved approximately 100,000 claims. Most recently, in May 2026, Bayer proposed a $7.25 billion settlement to resolve current and future cancer-related claims, with preliminary approval granted by a Missouri judge on May 4, 2026. The central allegation in these cases is that Bayer (which acquired the product through its purchase of Monsanto) failed to warn consumers and users that glyphosate, Roundup’s active ingredient, carries an increased risk of non-Hodgkin’s lymphoma.
Juries in several cases have sided with plaintiffs, awarding verdicts in the millions. Most significantly, the U.S. Supreme Court is currently reviewing Bayer’s appeal of a $1.25 million Missouri jury verdict, which raises fundamental questions about whether federal pesticide regulations preempt state-level failure to warn claims. The U.S. Solicitor General has sided with Bayer on the preemption question, arguing that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) prevents states from imposing additional warning requirements. However, 17 attorneys general—led by California—filed an amicus brief opposing preemption, asserting that states retain the authority to protect their citizens through failure to warn liability.
HOW THE SUPREME COURT’S PREEMPTION RULING COULD RESHAPE FAILURE TO WARN LAW
The Supreme Court’s pending decision in the Roundup case addresses whether FIFRA—the federal law governing pesticide labels and registration—preempts state failure to warn claims. This is not merely a technical legal question; the outcome will determine whether hundreds of billions of dollars in potential liability can proceed or whether federal approval of a pesticide label effectively shields manufacturers from state-level lawsuits. If the Court sides with Bayer and finds preemption, it would dramatically narrow failure to warn claims against pesticide manufacturers nationwide and could influence how courts approach federal preemption in other industries.
Conversely, if the Court rejects the preemption defense, state-level failure to warn claims will continue to thrive, and manufacturers will face significant pressure to include warnings on federally approved labels or face potential liability. This tension between federal and state regulation reflects a broader challenge in products liability law: the desire for uniform, predictable national standards conflicts with the traditional state authority to protect consumer safety. Several states have introduced legislation (2024–2026) that would make federally registered pesticide labels a complete defense to state failure to warn claims, suggesting that if the Supreme Court does not provide preemption, legislatures may attempt to do so.
OTHER MAJOR FAILURE TO WARN CASES CURRENTLY ACTIVE
Beyond Roundup, several other significant failure to warn litigations are advancing through the courts. Talcum powder products marketed by Johnson & Johnson have faced failure to warn claims regarding asbestos contamination and mesothelioma risk. In August 2025, a jury awarded $42.6 million in the Paul Lovell case for design defects and failure to warn, demonstrating that even after major settlements, individual verdicts continue to accumulate.
Similarly, Suboxone, a medication for opioid addiction, faces ongoing litigation centered on the claim that the manufacturer failed to adequately warn about dental consequences, including tooth decay and tooth loss, which some users experienced after extended use. Additionally, Depo-Provera (a contraceptive injection) cases remain in discovery with bellwether trials expected in 2026, involving allegations that manufacturers failed to warn about bone density loss and increased fracture risk. These cases highlight that failure to warn litigation extends far beyond pesticides and agricultural products; pharmaceutical manufacturers, medical device makers, and consumer product companies all face exposure. The diversity of products involved—ranging from talc to injectable medications to crop chemicals—underscores that the legal theory of failure to warn remains a potent tool for plaintiffs across many industries.
BUILDING A FAILURE TO WARN CASE: WHAT EVIDENCE MATTERS
To succeed in a failure to warn claim, plaintiffs typically need to gather several categories of evidence. Medical or scientific literature establishing that the hazard was known or knowable at the time the product was sold is critical. Internal company documents—including research files, risk assessments, and communications between scientists and marketing teams—can reveal that the manufacturer knew of the danger but chose not to warn.
Expert testimony from toxicologists, epidemiologists, or other specialists may be necessary to establish that the hazard was substantial and that a warning would have been feasible. Comparative labeling analysis also matters: plaintiffs often compare the warnings on the defendant’s product with warnings on competing products or warnings the manufacturer provided in other jurisdictions, arguing that if warnings were included elsewhere, they were clearly feasible. Additionally, evidence of the plaintiff’s actual use and exposure—supported by medical records, work history, or product purchase documentation—anchors the case in the individual plaintiff’s circumstances. In mass tort settings, establishing a consistent pattern of injuries across many users strengthens the claim that the failure to warn caused widespread harm rather than isolated incidents.
THE EVOLVING LANDSCAPE AND FUTURE OF FAILURE TO WARN LITIGATION
The failure to warn doctrine is rapidly evolving, driven by scientific advances, regulatory changes, and shifting judicial philosophies. As climate science and toxicology discover new hazards associated with established products, manufacturers will face ongoing pressure to update warnings or face liability. The Supreme Court’s decision on Roundup preemption will likely set the stage for similar battles in other regulated industries, particularly pesticides and pharmaceuticals where federal approval does not necessarily foreclose state liability.
Looking forward, manufacturers are increasingly adopting more expansive warning strategies, including digital warnings, QR codes linking to detailed safety information, and real-time warning updates. Additionally, some companies have moved toward reformulation or removal of problematic ingredients rather than relying solely on warnings—a strategic shift that reflects the high costs of failure to warn litigation. As artificial intelligence and data analytics improve the ability to detect hazards from post-market data, regulators and courts may impose stricter obligations on manufacturers to update warnings as new evidence emerges, making failure to warn claims both more accessible to plaintiffs and more expensive to defend.
Conclusion
A failure to warn lawsuit holds manufacturers accountable when they fail to provide adequate warnings about known or knowable product hazards. The legal standard is straightforward: if a feasible warning was absent and that absence contributed to injury, the manufacturer faces strict liability. The scope of current litigation—spanning pesticides, pharmaceuticals, talc products, and medical devices—illustrates the breadth of this legal theory and its significance in protecting consumers.
If you believe you have been harmed by a product due to inadequate warnings, consulting with a products liability attorney is essential. An attorney can evaluate whether your circumstances meet the legal elements of a failure to warn claim, gather necessary evidence, and determine whether you may be eligible to join existing litigation or pursue an individual claim. Time limits apply in most jurisdictions, so prompt action is important to protect your rights.